Core Viewpoint - Merus N.V. is participating in the 2025 Wells Fargo Healthcare Conference, highlighting its focus on innovative oncology therapies [1]. Company Overview - Merus N.V. specializes in developing full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics® [3]. - The company’s products, including Biclonics®, Triclonics®, and ADClonics®, are designed to have characteristics similar to conventional human monoclonal antibodies, such as long half-life and low immunogenicity [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will engage in a fireside chat at the conference on September 4, 2025, at 3:45 p.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].

Core Insights - Merus N.V. has granted non-statutory stock options to two new employees as an inducement award outside the 2016 Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4) [1] - A total of 240,000 shares of common stock were granted, with an exercise price of $65.56 per share, the closing price on August 1, 2025 [1] - The stock options have a ten-year term and vest over four years, with 25% vesting on the first anniversary of the hire date and the remainder vesting in equal monthly installments over the following three years [1] Company Overview - Merus is an oncology company focused on developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics® [2] - Multiclonics® are produced using industry-standard processes and have demonstrated features similar to conventional human monoclonal antibodies, including long half-life and low immunogenicity [2]